0 Members and 1 Guest are viewing this topic.
'It saved my life': Relative of party drug 'Special K' could revolutionize depression treatmentJohn Bacon, USA TODAYPublished 12:43 p.m. ET March 6, 2019 | Updated 1:50 p.m. ET March 6, 2019U.S. health officials have approved a medication related to the mind-altering drug ketamine as a new option for patients with severe depression. (March 6) APA new medication related to the iconic party drug "Special K" that can rapidly treat depression could revolutionize treatment of the condition affecting more than 16 million Americans, experts say.A subsidiary of Johnson & Johnson has won fast-track approval from the Food and Drug Administration for use of the drug esketamine in conjunction with an oral antidepressant for adults who have tried at least two other treatment options without success.Read more at: https://www.usatoday.com/story/news/nation/2019/03/06/esketamine-nasal-spray-drug-could-transform-treatment-depression/3077883002/
A new drug shows promise for depression, so naturally Scientology is fighting it... The Citizens Commission on Human Rights is by far Scientology’s angriest front group. CCHR accuses, taunts, and mocks mental health professionals, accusing them of torture similar to the Holocaust. It maintains two permanent “Industry of Death†museums in Los Angeles and Clearwater and traveling museums that pop-up in cities around the world that have an Ideal Org. CCHR opposes all forms of mental health treatment other than Dianetics. It lobbies the U.S. Congress and state legislatures to restrict medicines and medical devices. Scientology has come out against FDA approval of a new drug, Spravato. CCHR claims that the FDA has a conflict of interest, having received money from the drug manufacturer, and that the drug is similar to the dangerous club drug ketamine. “If approved, it would add to the mind-numbing of America that an FDA-psychiatric collusion is causing.†On Tuesday the FDA approved Spravato over the objections of Scientology. Not that its opposition would carry any weight, but CCHR was too late, having missed the approval of the FDA Advisory Committee back on February 12. The Spravato application received Fast Track and Breakthrough Therapy designations that sped up the process significantly. ...
Here's an interesting angle to this story:Rest of story